104 related articles for article (PubMed ID: 12815489)
1. Utility of antigenemia test for cytomegalovirus detection in hematopoietic transplant recipients: report of experiences from Medellín, Colombia.
Sarmiento-Maldonado M; Eugenia Castaño-Orozco M; Bedoya-Escobar VI; Calle-Fernandez S; Velásquez-Lopera M; Gomez-Wolff R; Karduss Urueta A; Cuellar-Ambrosi F
Bone Marrow Transplant; 2003 Jul; 32(1):119-20. PubMed ID: 12815489
[No Abstract] [Full Text] [Related]
2. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation.
Mori T; Mori S; Kanda Y; Yakushiji K; Mineishi S; Takaue Y; Gondo H; Harada M; Sakamaki H; Yajima T; Iwao Y; Hibi T; Okamoto S
Bone Marrow Transplant; 2004 Feb; 33(4):431-4. PubMed ID: 14676775
[TBL] [Abstract][Full Text] [Related]
3. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
[TBL] [Abstract][Full Text] [Related]
4. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients.
Cortez KJ; Fischer SH; Fahle GA; Calhoun LB; Childs RW; Barrett AJ; Bennett JE
J Infect Dis; 2003 Oct; 188(7):967-72. PubMed ID: 14513415
[TBL] [Abstract][Full Text] [Related]
8. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
[TBL] [Abstract][Full Text] [Related]
10. Role of quantitative human cytomegalovirus PCR in predicting antiviral treatment response among high-risk hematopoietic stem-cell transplant recipients.
Safdar A; Bruorton M; Henslee-Downey JP; van Rhee F
Bone Marrow Transplant; 2004 Feb; 33(4):463-4. PubMed ID: 14716349
[No Abstract] [Full Text] [Related]
11. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease.
Ruiz-Argüelles GJ; Rangel JD; Ponce-de-León S; González-Déctor L; Reyes-Núñez V; Garcés-Eisele J
Am J Hematol; 2004 Apr; 75(4):200-4. PubMed ID: 15054809
[TBL] [Abstract][Full Text] [Related]
12. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
Asano-Mori Y; Oshima K; Sakata-Yanagimoto M; Nakagawa M; Kandabashi K; Izutsu K; Hangaishi A; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
Bone Marrow Transplant; 2005 Nov; 36(9):813-9. PubMed ID: 16151428
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
[TBL] [Abstract][Full Text] [Related]
14. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes.
Habib K; Lamia T; Amel L; Abdelrahmen A; Saloua L; Hana E; Amine S; Bechir Z; Tarek BO; Assia BH
Exp Clin Transplant; 2008 Mar; 6(1):67-73. PubMed ID: 18405248
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
16. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
[TBL] [Abstract][Full Text] [Related]
17. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
18. HLA-DRB1*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation.
Du J; Liu J; Gu J; Zhu P
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1417-21. PubMed ID: 18022570
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients.
Correia-Silva Jde F; Victória JM; Guimarães AL; Salomão UE; de Abreu MH; Bittencourt H; Gomez RS
Oral Dis; 2007 Mar; 13(2):163-9. PubMed ID: 17305617
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Reddy V; Meier-Kriesche HU; Greene S; Schold JD; Wingard JR
Biol Blood Marrow Transplant; 2005 Sep; 11(9):698-705. PubMed ID: 16125640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
